Ongoing TrialsRSS

Welcome

TIMI stands for ‘Thrombolysis In Myocardial Infarction’ and is the name of an Academic Research Organization (ARO) that, since it was founded by Dr. Eugene Braunwald in 1984, has conducted numerous practice-changing clinical trials in patients with cardiovascular disease or risk factors for cardiovascular disease.

The TIMI Study Group is affiliated with Brigham and Women’s Hospital and Harvard Medical School, and is chaired by Dr. Marc Sabatine. Its offices are located in Boston, MA.

Learn More

Recent News and Publications RSS

• ELEVATE-TIMI 56: Late Breaking Clinical Trial Results
• ATLAS ACS 2 – TIMI 51: Late Breaking Clinical Trial Results
• The TIMI Trials Book 2010
• 2011.01 – GDF-15 and risk of recurrent events after ACS: observations from PROVE IT-TIMI 22
• 2010.11 – Clopidogrel with or without omeprazole in coronary artery disease
• 2011.01 – Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 Trial
• 2010.10 – Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
• 2010.08 – Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial